Lantheus expands its oncology portfolio in an all-cash transaction, adding Octevy, a registrational-stage positron emission tomography (PET) diagnostic agent for certain neuroendocrine tumors (NETs).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback